Know Cancer

forgot password

Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease - A Pilot Intervention Study

Phase 1
21 Years
55 Years
Not Enrolling
Anemia, Sickle Cell

Thank you

Trial Information

Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease - A Pilot Intervention Study

SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and
intense episodes of pain, which are called "sickle cell crises." In the past, SCD was
considered a fatal disease, and many people with SCD died at a young age. Due to advances in
medical care, people with SCD are now living longer lives; however, they often experience a
deterioration in quality of life due to progressive organ failure. Past research has
suggested that children with SCD commonly have frontal lobe dysfunction syndrome, which is a
brain disorder that can affect cognitive functioning in areas such as attention,
concentration, information processing, and decision making. Often times, however,
neurocognitive and brain disorders are not diagnosed or treated in people with SCD. In
preliminary brain imaging studies, at least half of adult participants with SCD had visible
cognitive dysfunction, while participants without SCD rarely had visible changes in the
brain. Brain dysfunction may be one of the most important and least-studied problems
affecting adults with SCD.

Most people with SCD have anemia, or low levels of red blood cells, which are the cells that
carry oxygen to the body's tissues, especially the brain. Research has shown that in people
with anemia who do not have SCD, memory and attention problems have decreased after
receiving treatment for anemia. The purpose of this study is to determine whether people
with SCD who receive monthly blood transfusions to treat their anemia experience greater
cognitive functioning than adults with SCD who receive usual care.

The first phase of this study was an observational study that enrolled adults with SCD and a
control group of healthy adults who did not have SCD. Study procedures included
questionnaires, neuropsychological testing, and MRI testing. At the end of the first phase,
participants were asked if they were willing to take part in a second phase of the overall
study in the future. Enrollment into the first phase ended in February 2008.

This current pilot study is the second phase of the overall study. In this study,
participants will begin by completing questionnaires, a medical history review, a physical
exam, a neurological exam, and a blood collection. Women will provide a urine sample for a
pregnancy test. An MRI and neuropsychological testing will also occur. Participants will
then be randomly assigned to receive either blood transfusions or usual care for 6 months.
Participants assigned to blood transfusions will receive the transfusions every 3 to 4 weeks
for 6 months. Before each transfusion, participants will undergo blood collection and a
review of medical history and medication history. Participants assigned to usual care will
receive a telephone call from study researchers at Months 1, 2, 4, and 5, at which time
medical and medication history will be reviewed. At study visits at Months 3 and 6, these
participants will also undergo a blood collection. At Month 6, all participants will
complete health and quality of life questionnaires, neuropsychological testing, and an MRI.

Inclusion Criteria:

- Completion of all components of the Phase 1 study (NCT00528801)

- Wechsler Adult Intelligence Scale (WAIS) III-Performance IQ (PIQ) score less than or
equal to 90

- Hemoglobin less than or equal to 9.0 g/dL

People who did not complete Phase I of the study are eligible for enrollment in this study
if they meet all of the following criteria:

- Capable of giving informed consent for the study

- Willing to undergo transfusion therapy for 6 months

- African descent

- Proficient/fluent in English

- Hemoglobin electrophoresis confirming hemoglobin SS or SB0 (less than or equal to

- WAIS III-PIQ score less than or equal to 90

- Hemoglobin less than or equal to 9.0 g/dL

- Mini-Mental Status Examination (MMSE) score of greater than or equal to 20

- Profile of Mood States (POMS) score on the Depression-Dejection Subscale less than or
equal to 40

Exclusion Criteria:

People who meet any of the following criteria are disqualified from enrollment in this

- History of life threatening or serious transfusion complications

- Lack of venous access

- Current enrollment in the Arginine study (NCT00513617)

- Pregnant

- Refusal of transfusion

- History of unexplained severe hemolytic transfusion reaction

- History of serious allergic, pulmonary transfusion reaction requiring hospitalization

- Positive auto-immune hemolytic anemia (direct Coombs test with IgG and complement)

- Multiple (three or more) clinically significant allo-antibodies, due to common
antigens (e.g., EC, Kel)

- Uncommon, clinically significant antibody that results in difficulty in finding
matched units (e.g., anti-JKB)

- Currently taking Hydroxyurea and not on a stable dose in the 6 months before study

- Creatinine level greater than 1.7 mg/dL

- Ferritin level greater than 1,500 ng/mL or quantitative liver iron level greater than
7 mg/g dry weight and not currently on iron chelation therapy. (This is a pilot
transfusion in which only 6 months of transfusion will be utilized. The likelihood of
iron overload induced toxicity from the transfusions over the 6 months is very small.
Furthermore, ferritin is disproportionately elevated in SCD and overestimates the
iron burden. Therefore, a quantitative liver iron and/or ferritin level has been
included as criteria for exclusion.)

- Major infarct identified on Phase I MRI

- Currently on Procrit or related drug that stimulates red blood cell production

In addition to the exclusion criteria listed above, people who did not complete Phase I
(or who completed Phase I more than 1 year prior to enrollment into this study) are
disqualified for enrollment in this study if they meet any of the following criteria:

- Overt stroke

- Previous evidence of an abnormal MRI or computed axial tomography (CT) scan other
than small periventricular or watershed lesions

- History of head injury that resulted in neurological symptoms or medical visit

- Abnormal neurological exam with focal findings

- Alcohol consumption exceeding 14 drinks/week if female or 21 drinks/week if male

- Drug abuse, as defined as using non-prescribed medication

- History of claustrophobia and/or presence of metallic implants such as pacemakers,
surgical aneurysm clips, or known metal fragments embedded in the body

- Baseline blood pressure greater than 140/90 mm Hg on two repeated measurements. A
second measurement is needed only if the first is greater than 140/90 mm Hg.

- History of uncontrolled hypertension

- Any long-term disorder that may result in neurocognitive or brain dysfunction that is
not secondary to SCD, including any of the following:

- Inflammatory arterial disorders (e.g., lupus, polyarteritis)

- History of cancer requiring chemotherapy and/or radiation

- Untreated hyperlipidemia

- Diabetes

- Ongoing active infection such as HIV, tuberculosis, or sarcoidosis

- History of long-term blood transfusion

- Long-term kidney failure/dialysis

- Long-term lung disease characterized by a need for oxygen

- Morbid obesity (i.e., weight greater than 115 kg)

- Heart disease, including a history of congestive heart failure, history of
severe coronary artery disease characterized by angioplasty or surgery, or
history of angina

- Active hepatitis or liver failure

- Acquired or congenital immune deficiency

- History of psychoses (e.g., delusions, hallucinations) and/or schizophrenia

- Neurodegenerative disorder

- Genetic disorder associated with neurocognitive dysfunction such as Down

- Other long-term illness or disorder other than SCD that will adversely affect
the person's performance in the study

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Cognitive function

Outcome Time Frame:

Measured at Month 6

Safety Issue:


Principal Investigator

Elliott Vichinsky, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Hospital & Research Center Oakland


United States: Federal Government

Study ID:




Start Date:

December 2004

Completion Date:

December 2010

Related Keywords:

  • Anemia, Sickle Cell
  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Hemoglobin SS
  • Hemoglobin SB0
  • Congenital Abnormalities
  • Anemia
  • Anemia, Sickle Cell



University of Texas Medical Branch Galveston, Texas  77555-1329
Boston Medical Center Boston, Massachusetts  02118
Howard University Washington, District of Columbia  20059
Medical College of Georgia Augusta, Georgia  30912
Duke University Medical Center Durham, North Carolina  27710
Washington University St. Louis, Missouri  63110
University Of Cincinnati Medical Center Cincinnati,, Ohio  45267-0589
Johns Hopkins Baltimore, Maryland  21231
University of North Carolina at Chapel Hill Chapel Hill, North Carolina  27599
Cincinnati Children's Hospital Cincinnati, Ohio  45229
University Of Miami Miller School Of Medicine Miami, Florida  33010
Memorial Cancer Institute Pembroke Pines, Florida  33028
Children's Hospital & Research Center at Oakland Oakland, California  94609
Karmanos Cancer Institute at Wayne State University Detroit, Michigan  48201